Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 22;6(60):eabj9256.
doi: 10.1126/sciimmunol.abj9256.

COVID-19 vaccine side effects: The positives about feeling bad

Affiliations

COVID-19 vaccine side effects: The positives about feeling bad

Jonathan Sprent et al. Sci Immunol. .

Abstract

The side effects of SARS-CoV-2 vaccines are often troubling but may merely reflect transient production of type I interferons, a normal physiological response to contact with invading microorganisms.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. mRNA vaccine activation of DC and induction of IFN-I.
After uptake, mRNA is translated into spike protein and presented as cell-surface MHC-bound peptides to CD4+ and CD8+ T cells. Cytosolic sensing of RNA by RIG-I and MDA5 plus TLR binding within endosomes leads to activation of IFN regulatory factor 3/7 (IRF3/7) and nuclear factor κB (NF-κB), which bind to DNA inducing gene transcription, and production of IFN-I and proinflammatory cytokines, respectively. MAVS, mitochondrial antiviral-signaling protein. Through up-regulation of DC costimulatory molecules, production of stimulatory cytokines, and a direct action on T cells, IFN-I guides and promotes the adaptive immune response of T and B cells.

References

    1. Wadman M., Public needs to prep for vaccine side effects. Science 370, 1022 (2021). - PubMed
    1. Remmel A., COVID vaccines and safety: What the research says. Nature 590, 538–540 (2021). - PubMed
    1. Schreiber G., The role of type I interferons in the pathogenesis and treatment of COVID-19. Front. Immunol. 11, 595739 (2020). - PMC - PubMed
    1. King C., Sprent J., Dual nature of type I interferons in SARS-CoV-2-induced inflammation. Trends Immunol. 42, 312–322 (2021). - PMC - PubMed
    1. Contoli M., Papi A., Tomassetti L., Rizzo P., Vieceli Dalla Sega F., Fortini F., Torsani F., Morandi L., Ronzoni L., Zucchetti O., Pavasini R., Fogagnolo A., Volta C. A., Bartlett N. W., Johnston S. L., Spadaro S., Campo G., Blood interferon-α levels and severity, outcomes and inflammatory profiles in hospitalized COVID-19 patients. Front. Immunol. 12, 648004 (2021). - PMC - PubMed

Publication types

MeSH terms